資源描述：
《補(bǔ)腎調(diào)肝清心方對(duì)圍絕經(jīng)期抑郁癥睡眠障礙大鼠模型海馬5-羥色胺1A受體、5-羥色胺2A受體的影響.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫(kù)。
1、環(huán)球中醫(yī)藥2014年6月第7卷第6期GlobalTraditionalChineseMedicine，June2014，Vo1．7，Nn6411·論著·補(bǔ)腎調(diào)肝清心方對(duì)圍絕經(jīng)期抑郁癥睡眠障礙大鼠模型海馬5一羥色胺1A受體、5．羥色胺2A受體的影響何軍琴尹曉丹辛明蔚【摘要】目的觀察補(bǔ)腎調(diào)肝清心方對(duì)圍絕經(jīng)期抑郁癥睡眠障礙模型大鼠海馬5。羥色胺1A受體(5一hydr0xytryptamine1Areceptor，5-HT1AR)、5-羥色胺2A受體(5-hydroxytryptamine2Arecep—tor，5
2、-HT2AR)的影響。方法將60只圍絕經(jīng)期大鼠按體重隨機(jī)分為5組，每組12只：圍絕經(jīng)期正常對(duì)照組(A)；圍絕經(jīng)期抑郁癥睡眠障礙模型組(B)；圍絕經(jīng)期抑郁癥睡眠障礙補(bǔ)佳樂(lè)治療組(C)；圍絕經(jīng)期抑郁癥睡眠障礙米氮平治療組(D)；圍絕經(jīng)期抑郁癥睡眠障礙中藥治療組(E)；A組為圍絕經(jīng)期正常大鼠，其余4組進(jìn)行18天不可預(yù)知慢性應(yīng)激。于應(yīng)激后對(duì)造模動(dòng)物進(jìn)行72小時(shí)連續(xù)快速眼相睡眠剝奪(REM)。每天在應(yīng)激前1小時(shí)按組給藥。在末次灌胃24小時(shí)后，頸椎脫臼法處死大鼠，取大鼠海馬，分別用熒光定量檢測(cè)海馬5-HT1ARmRNA
3、和5-HT2ARmRNA、蛋白印跡和免疫熒光檢測(cè)海馬5-HT1AR和5-HT2AR的表達(dá)。結(jié)果蛋白印跡檢測(cè)(westernblot)海馬及免疫熒光檢測(cè)海馬CA1區(qū)均顯示：海馬區(qū)5-HT1AR表達(dá)水平各組無(wú)明顯差異(P>0．05)，而5-HT2AR表達(dá)水平上，模型組顯著低于正常組(P<0．05)，治療組提高了5-HT2AR的表達(dá)水平，且與模型組相比存在顯著性差異(P<0．05)；RT—PCR顯示：海馬區(qū)5-HT1ARmRNA水平各組無(wú)明顯差異(P>0．05)，而5-HT2ARmRNA水平，模型組明顯低于正常組
4、(P<0．01)，米氮平組較模型組有極顯著性差異(P<0．001)，中藥組較模型組有顯著性差異(P<0．05)。結(jié)論補(bǔ)腎調(diào)肝清心方能提高5-HT2AR的mRNA及蛋白水平的表達(dá)，免疫熒光的結(jié)果表明在海馬CA1區(qū)發(fā)揮作用，表明補(bǔ)腎調(diào)肝清心方可以通過(guò)調(diào)節(jié)海馬CA1區(qū)5-HT2AR表達(dá)來(lái)改善睡眠障礙。【關(guān)鍵詞】圍絕經(jīng)期抑郁癥睡眠障礙；補(bǔ)腎調(diào)肝清心方；5-羥色胺1A受體；5-羥色胺2A受體【中圖分類號(hào)】R285．5【文獻(xiàn)標(biāo)識(shí)碼】Adoi：10．3969／j．issn．1674—1749．2014．06．003Efe
5、ctofBushenTiaoganQingxindecoctiononhippocampal5-HT1Aand5-HT2Areceptorofperi·menopaus~depressionmodelratsHEJun—qin，YINXiao—dan，XINMing—wei．BengObstetricsandGynecologyHospital，CapitalUnive~ityofMedicalSciences，Bering100026，ChinaCorrespondingauthor：HEJun—qin，
6、E—mail：junqinhe@sina．tom【Abstract】ObjectiveObservetheeffectofBushenTiaoganQingxindecoctiononhippocampal5一HT1Aand5-HT2AreceptorofPerimenopausaldepressionmodelrats．Methods60perimenopausalratswererandomlydividedinto5groups，12ratsineachgroup．Thenormalgroup(A)；
7、perimenopausalde—pressionsleepdisordermodelgroup(B)；perimenopausaldepressionsleepdisorderprogynovatreatmentgroup(C)；perimenopausaldepressionsleepdisordermirtazapinetreatmentgroup(D)；perimenopausaldepressionsleepdisorderTCMtreatmentgroup(E)．Agroupisperimeno
8、pausalnormalrats，theother4groupswereunder18daysofunpredictablechronicstress．Afterthelastadministration，theratswerekill—edbycervicaldislocationtogetthehippocampusandtestthe5-HT1AreceptormRNAand5-HT2Arecep—torm
